Table 4A Clinical benefit achieved from subsequent lines of endocrine therapy in patients with de novo resistance to 1^st line endocrine therapy

*Lines of Endocrine therapy*	2 ^nd *line*	3 ^rd *line*	4 ^th *line*
N	17	9	4
N of CB (%)	5 (29.4)	2 (22.2)	0
Median DOR with CB (months)	12.0 (7–29)	14.0+(11–17)	Not applicable
N still receiving treatment	0	1	0

+ = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; CB = Clinical Benefit; DOR = Duration of Response

ISSN: 1477-7819